Search research articles
Contact Us
Filters
Showing results (81-90 of 87) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 87 results.
ESMO Open
|
November 16, 2024
Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients
S Genta, D V Araujo, K Hueniken, et al.
ESMO Open
|
August 3, 2022
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
E Borazanci, A M Schram, E Garralda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M D Hellmann, T-W Kim, C B Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2025
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers
M M Gounder, P Martin-Romano, A Italiano, et al.
Frontiers in Oncology
|
October 22, 2025
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma
J-P Machiels, Y Tao, L Licitra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2022
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
A T C Chan, V H F Lee, R-L Hong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2026
ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
K S Saini, M Koopman, D Martins-Branco, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 87) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 87 results.
ESMO Open
|
November 16, 2024
Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients
S Genta, D V Araujo, K Hueniken, et al.
ESMO Open
|
August 3, 2022
Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
E Borazanci, A M Schram, E Garralda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 29, 2019
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M D Hellmann, T-W Kim, C B Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2025
Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers
M M Gounder, P Martin-Romano, A Italiano, et al.
Frontiers in Oncology
|
October 22, 2025
Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma
J-P Machiels, Y Tao, L Licitra, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2022
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
A T C Chan, V H F Lee, R-L Hong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2026
ESMO Adaptation of Lines of Systemic Therapy (EnLiST): a consensus framework for standardising the designation of lines of therapy in solid tumours
K S Saini, M Koopman, D Martins-Branco, et al.
Page
of 9